摘要
目的探讨协同共刺激分子B7-H3在膀胱尿路上皮癌患者血清水平及其临床意义。方法用ELISA方法检测膀胱癌,包括低度恶性潜能乳头状尿路上皮肿瘤(PUNLMP)、膀胱乳头状瘤和健康志愿者血清游离B7-H3水平,结合患者临床资料评估其对膀胱癌患者的临床意义。结果膀胱癌患者血清存在B7-H3,与乳头状瘤和正常志愿者相比,其水平显著增高(P<0.01)。但PUNLMP患者游离B7-H3水平与乳头状瘤和正常志愿者相比的差异无统计学意义(P>0.05)。膀胱癌患者游离B7-H3高水平与膀胱癌临床分期、淋巴结转移和组织分化程度有关,与性别无关。结论膀胱癌患者血清游离B7-H3水平可显著上调,与疾病进展有关,且患者预后较差。
Objective To explore the expression level and clinical significance of the co-stimulatory molecule B7-H3 in blood serum of bladder carcinoma patients. Methods The blood serum B7-H3 expression was detected by using ELISA kits in bladder cancer (including papillary urothelial neoplasms of low malignant potential, PUNLMP), urothelial papilloma and healthy volunteers to evaluate their clinical significance by combining clinical characteristics. Results There was a soluble form of BT-H3 (sBT-H3) in the blood serum of bladder cancer. The level of sB7-H3 expression in human bladder cancer were signifi- cantly higher than those in urothelial papilloma and healthy volunteers (P〈0.01). But the level of sB7-H3 expression in PUN- LMP have no statistical significance than those in urothelial papilloma and healthy volunteers (P〉0.05). A high level of sB7- H3 in patients with bladder cancer was found to be correlated with the clinical stage, lymph node metastasis and differentiation degree, and there were unrelated with gender. Conclusion The sB7-H3 expression level is significantly upregulated in blood ser- um of bladder carcinoma patients, indicating that B7-H3 dysregulation may be important in the progression of bladder cancer, and the high level of sB7-H3 expression represents a poor prognosis of human bladder cancer.
出处
《福建医药杂志》
CAS
2015年第3期5-7,共3页
Fujian Medical Journal
基金
福建省卫生厅青年科研课题(2012-2-3)